RESprotect History at a Glance

2000   RESprotect founded as a Fraunhofer-Society spin-off.


2002   Start of the development of next generation product candidates.

2004   Excellent results in a clinical pilot study led to out-licensing of the North-American rights of the company's first drug RP101 to Avantogen Ltd./Los Angeles.

2007   Excellent results in a second clinical study led to transfer of the North-American rights of RP101 to SciClone Pharmaceuticals, USA.

2008   Excellent results in out-licensing of the Korean rights of RP101 to Kwang Dong Pharmaceuticals/Seoul, South Korea.

2008-2009   Phase II double blind study with pancreatic cancer patients.

2008   Hsp27 confirmed as the novel and unique target of RP101.

2010   Orphan Drug status for RP101, SME status for RESprotect.

2011   RESprotect received back the North-America rights for RP101 from SciClone Pharmaceuticals and is currently aiming for strategic partnerships to develop and market RP101 and its next generation product candidates on a worldwide basis.